1. Talzenna is used to treat a specific form of BRCA-mutated, HER2-negative advanced or metastatic breast cancer.
2. The FDA also approved the BRACAnalysis CDx test as a companion diagnostic test to Talzenna to identify patients who would benefit from the drug.
3. Yutiq is an intravitreal implant used to treat a rare eye condition called chronic non-infectious uveitis.
4. Hemlibra is now the first prophylactic treatment for patients with hemophilia A with or without factor VIII inhibitors.
5. Liletta, an intrauterine device, may now be used to prevent pregnancy for up to five years.
More articles on supply chain:
9 things to know about the hospital-owned generic drug company
The first self-fitting hearing aid, a blood compatibility test & more: 5 latest FDA approvals
Blood bank issues urgent call for donors in wake of Hurricane Michael
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
